SOLV · Q2 2025 Earnings
BullishSolventum
Reported August 7, 2025
30-second summary
Solventum delivered Q2 revenue of $2.16B (+3.9% YoY, organic +2.8%) with non-GAAP EPS of $1.69, and used the print to lift FY25 EPS guidance to $5.80–$5.95, organic growth to +2.0–3.0%, and PNF deal accretion to $0.25–$0.30 — a coordinated raise that reframes the spin from survival mode into a value-creation story. Tariff headwind was cut to $60–80M (from $80–100M), operating margin is tracking toward the midpoint of the 20–21% plan range, and five named growth drivers (NPWT, IV site management, sterilization assurance, core restoratives, RCM) are doing the heavy lifting. The watch into 2H is whether normalized organic growth holds at the implied ~2.5% midpoint once the Q1 order-timing benefit reverses, primarily in Q3.
Headline numbers
EPS
Q2 FY2025
$1.69
Revenue
Q2 FY2025
$2.16B
+3.9% YoY
Gross margin
Q2 FY2025
54.4%
Free cash flow
Q2 FY2025
$0.06B
Operating margin
Q2 FY2025
9.9%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $2.16B | +3.9% |
| EPS | $1.69 | — |
| Gross margin | 54.4% | — |
| Operating margin | 9.9% | — |
| Free cash flow | $0.06B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| MedSurg | $1.218B | +4.8% |
| Dental Solutions | $0.338B | +2.3% |
| Health Information Systems | $0.339B | +3.4% |
| Purification and Filtration | $0.252B | +5.4% |
| Advanced Wound Care | $0.467B | +1.7% |
| Infection Prevention and Surgical Solutions | $0.75B | +6.9% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Organic Sales Growth (Q2) | 2.8% |
| Adjusted Operating Margin (Q2) | 21.9% |
| MedSurg Operating Margin | 17.3% |
| Dental Solutions Operating Margin | 28.5% |
| Health Information Systems Operating Margin | 35.5% |
| Purification and Filtration Operating Margin | 19.2% |
| Operating Cash Flow (Q2) | $169M |
| Full-Year Organic Sales Growth Guidance | +2.0% to +3.0% |
Management tone
Management's posture on this call read as confident and forward-looking — distinctly past the cautious-spinoff register that typically dominates early-quarters communication from companies recently separated from a parent. CEO commentary opened with "we are continuing where we left off in Q1, delivering another solid quarter" and closed with the assertion that "the foundation we inherited combined with the aggressive actions we've already taken positions us well for continued growth and margin acceleration." The shift from inheritance-framing to ownership-framing is the dominant tonal signature of the quarter.
The most concrete tonal upgrade came on tariffs. Initial framing was an $80–100M headwind treated as a known risk; this quarter management narrowed it to $60–80M with favorable timing skewed away from Q3, citing "improved estimates for US and China tariff rates." The shift moved tariffs from "thing we're managing" to "tailwind to the raise."
On organic growth, the narrative moved from defending a 1.5–2.5% range to raising it to 2–3% on the back of what management called "continued and underlying momentum in our business and markets." The bridge work in Q&A — Travis Steed of BofA pushing on the underlying 2.8% versus reported 0.8% — was handled with quantified detail rather than hedging, which itself signals confidence.
On M&A and capital allocation, the framing shifted notably. Asked about bolt-ons to hit the 4–5% LRP organic growth target, management called M&A "an enhancement, not a requirement" and said current organic performance is "squelching doubt" on LRP achievability. That's a meaningfully more assertive stance than typical post-spin capital-allocation rhetoric.
Where management remained guarded: the drinking water divestiture timing ("not urgent... want to find the right home") and any sizing of the Ensemble autonomous-coding opportunity — both deliberately vague.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Jason Bedner · Viper Sandler
What is driving MedSurg organic growth, particularly given the pull-forward from last quarter? What should we expect for growth trajectory in the back half with favorable comps?
Management attributed MedSurg momentum to three levers: (1) commercial restructuring and specialization creating cultural change and incentive alignment, (2) leveraging differentiated legacy brands with real clinical value (undersold in market), and (3) new product launches in sterilization assurance, negative pressure wound therapy, and IPNSS. Management expects continued acceleration. On second half cadence: normalized first half growth of 2.5% (excluding 1% order timing benefit); second half guide of 2.5% at midpoint when accounting for order pullback.
Travis Deed · Bank of America
Can you bridge the reported 0.8% growth to underlying growth, accounting for order timing, patient recall, ERP, and SKU rationalization? How should we think about underlying growth trajectory going forward?
Management indicated 2.8% reported growth represents realistic underlying growth after accounting for multiple puts and takes. Order timing was less impactful in Q2 than Q1 but still benefited infection prevention and surgical solutions. SKU rationalization impact doubled to 60 basis points in Q2 vs. Q1. For forward outlook, SKU headwind will increase to 100 basis points in 2026 (vs. 50bps in 2025). Management expects growth acceleration through three vectors: continued commercial restructuring dividends, new product launches in 2026, and relaunch of clinically relevant but underpenetrated legacy brands.
Patrick Cruz · Morgan Stanley
As the balance sheet improves post-separation, how are you thinking about capital allocation between bolt-on M&A and organic growth to achieve mid-single digit long-term growth targets?
Management characterized M&A as an enhancement, not a requirement, to achieve 4-5% mid-single digit organic growth outlined in long-range plan. Current organic performance is 'squelching doubt' on ability to reach targets. M&A would serve to potentially accelerate or overachieve targets, but is not necessary. Management expressed confidence that organic levers alone are sufficient.
Rick Wise · Stifel
What is the timeline and impact of the major ERP implementation in EU? How will we see positive implications—working capital, cash flow? When might you pursue a transaction for the drinking water business?
Management indicated the large EU ERP implementation is on track with challenges overcome. Smaller implementations planned through rest of 2024; next large cutover in 2026 (two instances); substantially complete by end of 2027. Separation costs expected to ramp down in 2026 and further in 2027. Free cash flow expected to improve significantly in 2026 and again in 2027 as separation costs cease. On drinking water: management wants to take time to prepare properly and find right home; not urgent; timing and specifics of transaction not being disclosed.
Stephen Valakit · Vizu Securities
Can you quantify the revenue opportunity from the Ensemble partnership for autonomous coding implementation across their 28 health system clients? What is the timing of rollout?
Management explained Ensemble is a revenue cycle management outsourcer absorbing FTE responsibility from health systems and using technologies like Encompass 360. Partnership creates marketing synergy and distribution channel. Ensemble will integrate autonomous coding into existing and new accounts to reduce service costs and improve margins. Autonomous coding still in early stages and not universally applicable. Management declined to size the opportunity but stated they wouldn't pursue partnership if not substantial. Revenue capture improvement expected through fewer coding mistakes. Relationship evolved through mutual trust and quality alignment, not competitive RFP.
What to watch into next quarter
Underlying organic growth normalization in Q3. Q3 carries the bulk of the order-timing reversal from Q1. Watch whether reported growth holds at or above ~1.5% (the implied 2H midpoint after the pullback) — anything below signals the raise was front-loaded optics.
MedSurg trajectory after the IPSS +6.9% print. Specifically whether sterilization assurance and NPWT launches sustain Q3 segment growth above 4%. A sub-4% MedSurg quarter would undermine the "commercial restructuring is working" thesis.
Advanced Wound Care recovery from the +1.7% recall-impacted quarter. Watch for a return to mid-single-digit growth; if it lingers below 3%, the recall was more than transitory.
Free cash flow ramp. 1H FCF of -$21M leaves the full $450–550M FY guide to be generated in 2H; Q3 needs a meaningful step-up to validate the FY range without back-end-loading entirely to Q4.
Tariff headwind realized. Management cut the range to $60–80M; watch the Q3 P&L disclosure to see whether the actual hit comes in below the new midpoint, providing room for another raise.
2026 SKU rationalization framing. Management telegraphed a 100 bps drag (vs. 50 bps in 2025). Watch for early 2026 organic growth framing on the Q3 or Q4 call — specifically whether ex-SKU growth remains anchored above 3%.
Sources
- Solventum Q2 2025 Form 8-K Exhibit 99.1 (press release) — https://www.sec.gov/Archives/edgar/data/1964738/000196473825000062/q22025-8kerexx991.htm
- Solventum Q2 2025 earnings call — analyst Q&A and management commentary (extraction-sourced)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.